(Alles Europa News) – In the United States, medical scientists have found an effective cure for cancer of the last fourth stage.
Alles Europa News reports that Nivolumab blocks the activity of the PD-1 molecule, which is an immune control point that restrains cells attacking a cancerous tumor.
Researchers at the Johns Hopkins Cancer Institute of Cancer Institute report successful trials of a new drug, nivolumab (anti-PD-1), to fight progressive and refractory treatments for cancers such as melanoma, renal cell carcinoma, or non-small cell carcinoma lungs.
Alles Europa News reports that 270 people took part in the study.
According to the results of a long-term trial of nivolumab, five-year survival rates for the new drug were higher than for other types of therapy, including chemotherapy, kinase inhibitors, biological therapy and other treatment methods.
Alles Europa News reports that With conventional therapy for patients with stage four skin cancer, five-year survival was five percent, and for non-small cell lung cancer, six percent.
Nivolumab contributed 34.2 percent survival for melanoma, 27.7 percent for renal cell carcinoma, and 15.6 percent for lung cancer.